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Abstract 
 
At present scenario the drug regimen based on circadian rhythm is recently gaining much 
attention worldwide by researchers. Justification behind it is that, there are various diseases like 
asthma, hypertension, and arthritis show circadian variation that demand time scheduled drug 
release for effective drug action. A chronodelivery system,based on biological rhythms, is a 
state-of the- art technology for drug delivery. The aim of present work is formulate and evaluate 
a press coated pulsatile release tablets of Cilnidipine using an admixture of hydrophilic polymer 
i.e. hydroxypropyl methyl cellulose (HPMC) and pH sensitive polymers (ethyl cellulose, 
eudragit S-100) in order to achieve a predetermined lag time for chronopharmacotherapy of 
Hypertension. Cilnidipine is the novel calcium antagonistaccompanied with L-type and N-type 
calcium channel blocking function used for the treatment of hypertension. 
The tablets prepared were evaluated for different properties like bulk density, tapped density, 
Angle of repose and Carr’s index), hardness, thickness, weight variation, friability, drug content 
uniformity and in vitro drug release study.  
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Introduction 
A pulsatile release profile is characterized by a lag time followed by rapid and complete drug 
release. Pulsatile drug delivery systems are designed according to the circadian rhythm of the 
body
1
. Chronomodulated system is also known as pulsatile system or sigmoidal release system 
related to biological rhythms. Circadian rhythm regulates many functions in human body like 
metabolism, physiology, behavior, sleep pattern, hormone production.Many diseases such as 
cardiovascular, asthma, peptic ulcer, arthritis etc. follow the body’s circadian rhythm and shows 
circadian pattern
2
. These conditions could be taken by timing and adjusting the administration of 
drugs according to the circadian rhythm of the disease. These systems are designed in a manner 
that the drug is available at the site of action at the right time in the right amount
3
. Disease 
conditions where constant drug levels are not preferred but need a pulse of therapeutic 
concentration in a periodic manner acts as a push for the development of pulsatile drug delivery 
system. A time delayed release profile is characterized by a lag timefollowed by rapid and 
complete drug release
4
. 
Cilnidipine is the novel calcium antagonist accompanied with L-type and N-type calcium 
channel blocking function. Cilnidipine decreases blood pressure and is used to treat 
hypertension
5,6,7
. Morning hypertension is a condition characterized by high blood pressure 
(≥135/85 mm Hg) in the morning and controlled levels throughout the day7. Heart attacks and 
stroke usually occur in the morning because of morning hypertension. Between 4:00AM and 
noon, the body releases certain hormones that boost energy and increase morning alertness, but 
this also results in a sharp increase in blood pressure
8
. 
So for effective treatment such type of drug delivery system required which provide minimum 
amount of drug release at night highest at morning. Through pulsatile delivery system this type 
of release can be provide. 
Thus, this study focus on the development of press coated pulsatile tablets of Cilnidipine for 
providing the relief from hypertension deliver the drug at specific time as 
 per pathophysiological needs of the disease and improvement of therapeutic efficacy and 
patient compliance. 
 
Material and method 
Material 
Lactose was obtained from Givanas Nigerial Ltd, microcrystalline cellulose, 
Crospovidone,Magnesium stearate, Dicalcium phosphate were  obtained from  Chemiron 
International Limited, Lagos, Nigeria. HPMC, EC and talc were obtained from Avro Pharma 
Limited, Lagos, Nigeria Eudragit S 100 was obtained from Archy Pharmaceutical Nigeria 
Limited. All other chemicals and reagents used were either of analytical or pharmaceutical 
grades. 
Tablet Manufacturing Method 
1. Formulation of core tablets by direct compression 
The core tablets containing Cilnidipine were prepared by using the composition shown in table 1. 
All excipients were mixed for 25 min and passed through a 40 mesh size sieve and directly 
compressed in to 70 mg tablets using 6 mm round flat punches on a rotarytablet machine
9
. 
2. Preparation of press coated pulsatile tablets 
The core tablets were press coated with polymer blend. Polymer blend was composed of HPMC, 
EC and Eudragit S 100 in different concentrations. Half of the coating material was placed in the 
die cavity, the core tablet was carefullypositioned in the centre of the die and cavity was filled 
with the other half of the coating material. Coating materials was compressed around the core 
tablet using of 10mm punch
10
. The compositions were as shown in table 2. 
Table 1: Composition of Cilnidipine core tablets 
Ingredients Quantity 
(mg) 
Cilnidipine 50 
Microcrystalline 
cellulose 
90 
Crospovidone 3 
Lactose 30 
Magnesium stearate 4 
Dicalcium phosphate 90 
Talc 5 
Total 272 
Table 2: Compression coat formula for different Cilnidipine tablet batches 
Ingredients 
       (mg) 
Batch Code 
CPT1 CPT2 CPT3 CPT4 
Core tablet 272 272 272 272 
HPMC 40 60 80 100 
EC 40 60 80 100 
Eudragit S 100 40 60 80 100 
 
Evaluation of core tablets 
A. Precompressional studies: 
1. Determination of angle of repose 
 The angle of repose of blend was determined by the funnel method. The accurately weight blend 
was taken in the funnel. The height of the funnel wasadjusted in such a way that the tip of the 
funnel just touched the apex of the blend. The blend was allowed to flow through the funnel 
freely on to the surface. The diameter of the powder cone was measured and angle of repose was 
calculated using the following equation
11
.  
tan θ= h/r 
Where, h and r are the height and radius of the powder cone. 
2. Determination of bulk density and tapped density 
Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. A quantity of 
2gm of blend previously shaken to break any agglomerates formed, then it was introduced in to 
10 ml measuring cylinder. After that the initial volume was noted and the cylinder was allowed 
to fall under its own weight on to a hard surface from the height of 2.5 cm at second intervals. 
Tapping was continued until no further change in volume was noted. LBD and TDB were 
calculated using the following equations
12
.  
LBD= (Weight of the granules)/(Untapped Volume of the packing) 
TBD= (Weight of the granules)/(Tapped volume of the packing) 
3. Determination of Compressibility Index 
The Compressibility Index of the blend was determined by Carr’s compressibility index. It is a 
simple test to evaluate the LBD and TBD of a powder and the rate at which it packed down
13
. 
The formula for Carr’s Index is as below:  
Carr’s Index (%) =(TBD-LBD)/TBD X100 
4. Hausner’s Ratio 
Hausner’s Ratio was determined by following equation14: 
Hausner^' s ratio= (Tapped density)/(Bulk density) 
B. Post-compressional studies: 
1. Uniformity of thickness 
Thickness of Cilnidipine tablets were measured using a calibrated dial calipers. Three tablets of 
each formulation were picked randomly and dimensions determined. It is expressed in mm and 
standard deviation was alsocalculated
15
. 
2. Weight variation test 
Twenty Cilnidipine tablets were selected randomly from each batch and weighed individually to 
check for weight variation
16
.  
3. Hardness test 
Hardness indicates the ability of a tablet to withstandmechanical shocks while handling. 
Hardness of Cilnidipine tablets was determined using a validated dial type hardness tester. It is 
expressed in kg/cm
2
. Three tablets were randomly picked from each batch and analyzed for 
hardness. The mean and standard deviation were also calculated
17
. 
4. Friability 
Twenty Cilnidipine tablets were weighed and placed in the Roche friabilator and apparatus was 
rotated at 25 rpm for 4 minutes18. After revolutions the tablets wereweighed again. The 
percentage friability was measured using the formula, 
% Friability=(Initial weight-Final weight)/(Initial weight)  X100 
5. Drug content 
Three Cilnidipine tablets were weighed individually and triturated. Powder equivalent to the 
average weight of the tablet was weighed and drug was extracted in water for 6 hours. The 
 solution was filtered through 0.45μ membrane. The absorbancewas measured at 291 nm after 
suitable dilution
19
.  
6. Lag time of coated tablets  
The lag time of pulsatile release Cilnidipine tablets is defined at the time when the outer coating 
starts to rupture. It was determined visually by using USP dissolution testing apparatus II (900ml 
buffer 37.0± 0.5 °C, 50 rpm).  Coated Cilnidipine tablets were evaluated for lag time in pH 6.8 
and 7.4 phosphate buffer respectively. Coated tablets were placed in 900 ml of above mentioned 
buffers, agitated at 75 rpm and maintained at 37±0.5
0
C. The timetaken for outer coating to 
rupture was monitored and reported as lag time
20
. 
7. Dissolution studies of the coated tablets 
Drug release study of coated Cilnidipine tablets was carried out using USP XXIII dissolution test 
apparatus I. Initially tablets were placed in 900 ml of 0.1 N HCl for 2 hours maintained at 
37±0.5
0
C, 75 rpm followed by pH 6.8 phosphate buffer for 3 hours and pH 7.4 for 5 hours. 
Aliquots of predetermined quantity were collected manually at definite timeintervals replacing 
with fresh buffer to maintain sink condition and analyzed for drug content using a UV-visible 
spectrophotometer at λ max of 291 nm21. 
 
Table 3: Pre compression parameters for coating materials 
Batch 
 code 
Bulk density 
(LBD) 
Tapped 
density 
(TBD) 
Carr’s index Hausner’s ratio 
 
Angle of 
repose 
(degree) 
CPT1 0.506± 0.06 0.603± 0.08 16.08± 0.06 1.191± 0.15 25.26± 0.07 
CPT2 0.513± 0.25 0.614± 0.11 16.4± 0.09 1.196± 0.08 26.03± 0.13 
CPT3 0.526± 0.18 0.625± 0.24 15.8± 0.11 1.188± 0.11 28.32± 0.15 
CPT4 0.543± 0.09 0.652± 0.33 16.7± 0.08 1.213± 0.09 27.51± 0.08 
 
Table 4-Post compression parameters for coated tablets 
Batch 
code 
Hardness 
(Kg/cm
2
) 
Thickness 
(mm) 
% 
Friability 
% Weight 
variation 
% Drug 
content 
Lag Time 
(min) 
CPT1 5.96± 0.11 4.72± 0.08 0.75± 0.12 273.25± 0.09 97.42± 0.12 255.47± 0.13 
CPT2 4.93± 0.08 5.24± 0.06 0.81± 0.13 242.42± 0.12 99.21± 0.06 278.34± 0.07 
CPT3 5.25± 0.06 5.31± 0.16 0.82± 0.06 311.51± 0.15 98.67± 0.21 280.47± 0.09 
CPT4 4.98± 0.21 5.62± 0.12 0.68± 0.21 322.34± 0.09 98.72± 0.13 300.58± 0.14 
 
Results and discussion 
In the present study, an attempt was made to design pulsatile drug delivery system of Cilnidipine 
for the effective treatment early morning hypertension. The pulsatile drug release tablets were 
prepared by compression coating method and consisted of two different parts: a core tablet, 
containing the active ingredient and an erodible outer coatinglayer of polymer. Based on 
preliminary trials, the core tablets of Cilnidipine were prepared by using different ingredients 
including microcrystalline cellulose, crospovidone, lactose, magnesium stearate, dicalcium 
phosphate and talc by direct compression technique. 
Results of the pre-compression parameters performed on the blend for batch (Table 3). 
The results of Hausner’s ratios were found to in the range of 1.188± 0.11 to 1.213± 0.09. 
The result of angle of repose ranged between 25.26± 0.07 to 28.32± 0.15. The values are less 
than 30, indicate good flow properties of powder base. This was further supported by lower 
compressibility index values. Generally, compressibility index values up to 15% results in good 
 to excellent flow properties. To obtain desired lag time before drug release, the core tablets were 
coated with varied ratio of HPMC, EC, Eudragit S 100 polymers to achievebarrier properties by 
compression coating technique. The compression coated tablets were evaluated for weight 
variation, thickness, hardness, friability, drug content and lag time. 
The hardness of tablets of all the formulations ranged between 4.93± 0.08 to 5.96± 0.11 kg/cm
2
. 
The formulation CPT1 showed a comparatively high hardness value of 5.96± 0.11 kg/cm
2
. This 
may be due to presence of higher amount of ethyl cellulose, which is generally responsible for 
more hardness. The percentage friability of tablets of all the formulations ranged between 0.68± 
0.21 to 0.82± 0.06. Percentage friability for all the formulations was below 1% indicating that 
the friability is within the prescribed limits. The % weight variation of tablets of all the 
formulations ranged between 242.42± 0.12 to 322.34± 0.09. The average percentage deviation of 
all the tablet formulations was found to be within the limit, and hence all the formulations passed 
the test for uniformity of weight as per the official requirements. 
Satisfactory uniformity in drug content was found amongdifferent batches of tablets, and 
percentage of drug content was more than 97.42± 0.12 %. 
Lag time of all the formulations was found between 255.47± 0.13 to 300.58± 0.14. A Cumulative 
percent drug released versus time showed in (Figure 1) the dissolution rate was inversely 
proportional to the coated level applied. The quick release was observed in tablets containing 
ethylcellulose, it may be due to high solubility of EC at pH 6.8. This polymer characteristic gives 
to the matrix a quick gel erosion rate and a high erosion degree of the overall system. Maximum 
drug release 94.39% was shown by the tablets of batch CPT1 and lowest release 73.54% by the 
tablets of batch CPT3 in the 10hrs study. 
 
Figure-1: Cumulative percentage drug release of coated 
tablets of Cilnidipine 
 
Conclusion 
A satisfactory attempt was made to develop pulsatile release Cilnidipine tablets using pH 
sensitive polymers (ethyl cellulose, eudragit S-100) and swellable hydrophilic polymer (HPMC) 
to mimic the circadian rhythm. Prepared pulsatile drug delivery systems were evaluated for 
hardness, friability, weight variation, drug content uniformity, in vitro drug release. 
Based on different evaluation parameters formulation of batchCPT1 was concluded as an 
optimum formulation. The system released the drug rapidly after a certain lag time due to the 
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 rupture of the polymers film. Pulsatile release Cilnidipine tablets can be taken at 
bedtime so that the content will be released in the morning hours i.e. at the time of symptoms. 
From the above results, it can be concluded that the prepared pulsatile drug delivery system can 
be considered as one of the promising formulation technique for chronotherapeutic management 
of hypertension. 
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